Appili Therapeutics Inc logo

APLI - Appili Therapeutics Inc Share Price

C$1.05 -0.0  -1.9%

Last Trade - 16/04/21

Micro Cap
Market Cap £38.1m
Enterprise Value £27.0m
Revenue £n/a
Position in Universe 1036th / 2713
Unlock APLI Revenue
Relative Strength (%)
1m -0.62%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -44.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Mar 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.20 21.5
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 31 December 2020, AppiliTherapeutics Inc revenues decreased from C$199K to C$0K.Net loss increased from C$4.1M to C$9.3M. Revenues reflecta decrease in demand for the Company's products andservices due to unfavorable market conditions. Higher netloss reflects Research and development - Remaining increasefrom C$959K to C$5M (expense), General and administrative -Balancing increase of 50% to C$1.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for APLI
Graphical History


APLI Revenue Unlock APLI Revenue

Net Income

APLI Net Income Unlock APLI Revenue

Normalised EPS

APLI Normalised EPS Unlock APLI Revenue

PE Ratio Range

APLI PE Ratio Range Unlock APLI Revenue

Dividend Yield Range

APLI Dividend Yield Range Unlock APLI Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
APLI EPS Forecasts Unlock APLI Revenue
Profile Summary

Appili Therapeutics Inc is a Canada-based pharmaceutical company. The Company is focused on the acquisition and development of treatments targeting infectious disease. The Company is focused on building and advancing adverse portfolio of anti-infective programs. The Company’s anti-infective portfolio includes ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. The ATI-2307 is a clinical-stage antifungal candidate in development for severe and difficult-to-treat invasive fungal infections. The ATI-1701 is a vaccine candidate for tularemia. The ATI-1503 is a drug discovery program aimed at generating a class of antibiotics with broad spectrum activity against gram-negative superbugs. The ATI-1501 employs its taste-masked, oral-suspension technology with metronidazole for the patients with difficulty swallowing.

Last Annual March 31st, 2020
Last Interim December 31st, 2020
Incorporated May 7, 2015
Public Since June 25, 2019
No. of Shareholders: n/a
No. of Employees: 11
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Toronto Stock Exchange
Shares in Issue 62,777,469
Free Float (0.0%)
Eligible for
APLI Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for APLI
Upcoming Events for APLI
Frequently Asked Questions for Appili Therapeutics Inc
What is the Appili Therapeutics Inc share price?

As of 16/04/21, shares in Appili Therapeutics Inc are trading at C$1.05, giving the company a market capitalisation of £38.1m. This share price information is delayed by 15 minutes.

How has the Appili Therapeutics Inc share price performed this year?

Shares in Appili Therapeutics Inc are currently trading at C$1.05 and the price has moved by 5% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Appili Therapeutics Inc price has moved by -21.96% over the past year.

What are the analyst and broker recommendations for Appili Therapeutics Inc?

There are no analysts currently covering Appili Therapeutics Inc.

When will Appili Therapeutics Inc next release its financial results?

Appili Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Appili Therapeutics Inc dividend yield?

Appili Therapeutics Inc does not currently pay a dividend.

Does Appili Therapeutics Inc pay a dividend?

Appili Therapeutics Inc does not currently pay a dividend.

When does Appili Therapeutics Inc next pay dividends?

Appili Therapeutics Inc does not currently pay a dividend.

How do I buy Appili Therapeutics Inc shares?

To buy shares in Appili Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Appili Therapeutics Inc?

Shares in Appili Therapeutics Inc are currently trading at C$1.05, giving the company a market capitalisation of £38.1m.

Where are Appili Therapeutics Inc shares listed? Where are Appili Therapeutics Inc shares listed?

Here are the trading details for Appili Therapeutics Inc:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: APLI
What kind of share is Appili Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Appili Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Appili Therapeutics Inc share price forecast 2021?

Shares in Appili Therapeutics Inc are currently priced at C$1.05. At that level they are trading at 0.14% discount to the analyst consensus target price of 0.00.

Analysts covering Appili Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.225 for the next financial year.

How can I tell whether the Appili Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Appili Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -39.43%. At the current price of C$1.05, shares in Appili Therapeutics Inc are trading at -7.25% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Appili Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Appili Therapeutics Inc.

Who are the key directors of Appili Therapeutics Inc?

Appili Therapeutics Inc's management team is headed by:

Brian Bloom - IND
Kimberly Stephens - CFO
Juergen Froehlich - IND
Ian Mortimer - CHM
Yoav Golan - OTH
Armand Balboni - CEO
Theresa Matkovits - IND
Myriam Triest - SDR
Don Cilla - OTH
Rochelle Stenzler - DRC
Who are the major shareholders of Appili Therapeutics Inc?

Here are the top five shareholders of Appili Therapeutics Inc based on the size of their shareholding:

Bloom Burton & Co. Inc. Research Firm
Percentage owned: 22.86% (14.4m shares)
K2 & Associates Investment Management Inc. Hedge Fund
Percentage owned: 8.37% (5.25m shares)
Similar to APLI
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.